[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligozoospermia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligozoospermia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,81,106,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100589006","phase-1-a-study-to-evaluate-the-safety-and-tolerability-of-single-and-multiple-dose-of-stsp-0902-in-healthy-subjects-100589006",false,"NCT06948799","A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects","A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Immunogenicity of STSP-0902 in Healthy Subjects","Inclusion Criteria:\n\n1. Male volunteers, aged between 18 and 50 years inclusive, with a body weight of at least 50.0 kg, and a body mass index (BMI) between 19.0 and 28.0 kg\u002Fm² inclusive.\n2. Participants in the multiple dose phase must meet one of the following criteria: two routine semen analysis results during the screening period meet the criteria of sperm concentration of less than 15 million and\u002For percentage of progressively motility sperm of less than 32%.\n3. Participants (including the partners of the participants) must use effective non-drug contraceptive measures during the trial period and for four months after the end of administration, and must not have plans for pregnancy or sperm donation.\n4. Participants should avoid high temperature environments during the trial, including saunas, steam baths, hot baths, hot springs, and the use of electric blankets.\n5. Participants must give informed consent to this study before the study and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Participants with a history of severe diseases, including but not limited to conditions affecting the skeletal, neuropsychiatric, cardiovascular, hematologic, hepatic, renal, gastrointestinal, respiratory, metabolic, endocrine, immune, and reproductive systems (such as reproductive system infectious diseases, varicocele, reproductive tract obstruction, etc., except for oligoasthenzoospermia), as judged by the investigator, may endanger the safety of the participant or affect the study results.\n2. Participants who have planned to receive treatments related to oligoasthenzoospermia, such as zinc sulfate, levocarnitine, escin, or pancreatic kallikrein, within 3 months prior to screening or during the trial period.\n3. Participants with a history of treatment with nerve growth factor-like drug therapy (such as mouse nerve growth factor for injection) within 3 months prior to screening.\n4. Participants who have undergone any major surgery within 3 months prior to screening or have surgery planned during the trial period.\n5. Participants who have experienced a fever exceeding 38 ℃ within 1 month prior to screening\n6. Pre-enrollment physical examination, electrocardiogram, vital signs, laboratory tests, and results of all tests related to the trial (except oligoasthenzoospermia), with abnormalities judged clinically significant by the investigator.\n7. Participants who are allergic to any component of the experimental drug or biological agent, or who, in the judgment of the investigator, are at risk of allergy as a result of participation in the study.\n8. Participants who are positive for any one of the hepatitis B surface antigen, hepatitis C antibody, treponema pallidum antibody, and HIV antigen\u002Fantibody combination test (primary screening).\n9. Tattoos at the injection site or other skin conditions that interfere with observation of the skin.\n10. Participants who have smoked more than 5 cigarettes per day or an equivalent amount of tobacco in the 3 months prior to screening.\n11. Participants with frequent alcohol consumption within 6 months prior to screening, i.e., more than 2 units of alcohol per day (1 unit = 360 ml of beer or 45 ml of spirits of 40% alcohol by volume or 150 ml of wine); or those with a positive alcohol breath test.\n12. Participants who have habitual consumption of more than 5 cups of coffee, tea or cola, etc. per day (150 ml and above per cup) in the 3 months prior to screening.\n13. Participants who have a history of drug abuse within 1 year prior to screening or have a positive urine drug test.\n14. Participants who have participated in blood donation within 3 months prior to screening with a total blood donation of ≥ 400 mL or total blood loss of ≥ 400 mL, or who have history of blood transfusion within 4 weeks prior to enrollment.\n15. Participants who have taken any investigational product or participated in any clinical trial of drug, devices or vaccines intervention within 3 months prior to screening.\n16. Vaccination within 1 month prior to screening or scheduled to be administered during the study period up to 2 months after completion of the study.\n17. Participants who have used any prescription, over-the-counter medications or herbal remedies within 14 days prior to screening.\n18. Participants with a history of fear of needles and homophobia.\n19. Participants with other factors that are not suitable for participation in this study as judged by the investigator.",true,"MALE","18 Years","50 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a Phase 1b, randomized, double-blind, placebo-controlled, single and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of STSP-0902",[28],"Oligozoospermia","RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2025-05-08",{"date":37,"type":22},"2026-08",{"name":39,"class":40},"Staidson (Beijing) Biopharmaceuticals Co., Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":41},"100621793","effect-of-daily-intake-of-gazpacho-on-semen-quality-and-oxidative-stress-100621793","NCT07375238","Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress","Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress in Men With Altered Semen Parameters: A Randomized Controlled Study","G-OXSEM","Inclusion Criteria:\n\n* Men aged 18 to 45 years\n* Andrological profile including altered semen parameters such as oligozoospermia, asthenozoospermia and\u002For teratozoospermia (O±A±T)\n* No clinical indication for sperm DNA fragmentation testing or advanced sperm selection techniques\n* Willingness and ability to comply with the study protocol, including adherence to a standardized Mediterranean diet\n* Signed and dated written informed consent form\n\nExclusion Criteria:\n\n* Use of antioxidant supplements during the three months prior to study start.\n* Active smokers or men who have stopped smoking within the last three months.\n* Diagnosis of azoospermia, leucocytospermia or necrozoospermia.\n* Presence of severe systemic diseases or chronic conditions that could interfere with semen quality or adherence to the study.\n* Known allergy or intolerance to any ingredient of the gazpacho used in the study.\n* Any medical, psychological or social condition that, in the investigator's judgement, could compromise the subject's ability to participate fully or comply with the protocol requirements.\n* Simultaneous participation in another clinical study.","45 Years",{"count":52,"type":22},80,[54],"NA","The goal of this clinical trial is to learn whether drinking a daily serving of gazpacho can improve semen quality in men with reduced sperm quality. The study will also examine how this dietary intervention affects oxidative stress and whether it is well tolerated.\n\nThe main questions this study aims to answer are:\n\n* Does daily consumption of gazpacho improve semen quality in men with altered semen parameters?\n* Does this dietary intervention affect levels of oxidative stress in semen?\n* Is daily gazpacho intake feasible and well tolerated as part of a Mediterranean diet?\n\nResearchers will compare a Mediterranean diet plus daily gazpacho intake with a Mediterranean diet alone to determine whether adding gazpacho provides additional benefits for male reproductive health.\n\nParticipants will:\n\n* Follow a standardized Mediterranean diet for 12 weeks\n* Drink 330 mL of gazpacho every day or follow the diet without gazpacho\n* Provide semen samples at the start of the study and after 12 weeks\n* Complete a short diary to record adherence to the dietary intervention\n* Be followed for up to 18 months to record reproductive outcomes",[57,58,59,28,60,61],"Male Infertility","Oxidative Stress","Subfertility","Asthenozoospermia","Teratozoospermia",[63,64,65,66,67,68,69,70],"Mediterranean diet","Gazpacho","sperm quality","Male infertility","Altered semen parameters","oxidative stress","OxiSperm II","Randomized trial","2026-03-11",{"date":73,"type":33},"2026-03-13",{"date":75,"type":33},"2026-03-02",{"date":77,"type":22},"2029-09-01",{"name":79,"class":80},"Ginefiv","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100573142","efficacy-and-safety-of-a-new-sperm-capacitation-method-100573142","NCT06742437","Efficacy and Safety of a New Sperm Capacitation Method","Efficacy and Safety of a New Sperm Capacitation Method: a Prospective in Vitro Study on Semen Samples","HyperSperm01","Inclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months","60 Years",{"count":91,"type":22},300,"OBSERVATIONAL","Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to evaluate the efficacy and safety of HyperSperm, a new sperm capacitation method, in 300 semen samples with various characteristics and abnormalities, in an in vitro study over 12 months.",[95,57,60,28,61],"Reproductive Issues","2026-02-24",{"date":98,"type":33},"2026-02-27",{"date":100,"type":33},"2025-01-14",{"date":102,"type":22},"2026-06",{"name":104,"class":80},"Fecundis Lab SL",4,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":50,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100619502","probiotics-on-sperm-quality-in-male-infertility-patients-100619502","NCT07345455","Probiotics on Sperm Quality in Male Infertility Patients","Effect of Probiotics on Sperm Quality in Male Infertility Patients","Inclusion Criteria:\n\n* Males aged 20 to 45 years\n* Diagnosis of unexplained oligozoospermia, asthenozoospermia, or oligoasthenoteratozoospermia\n* Sperm concentration \\\u003C 5 x 10\\^6\u002FmL\n* Sperm total motility \\\u003C 40%\n* Sperm morphology (Kruger strict criteria) \\\u003C 4%\n\nExclusion Criteria:\n\n* History of hormonal disorders or epididymo-orchitis\n* Substance abuse, including drugs or excessive alcohol consumption\n* Diabetes mellitus\n* Kidney disease (defined as a doubling of creatinine levels or more)\n* Chronic liver disease\n* Varicocele\n* Current use of medications that interfere with hormones\n* Occupational or environmental exposure to pesticides, heavy metals, or solvents\n* Intake of antioxidant supplements within the past three months\n* Body Mass Index (BMI) of 30 kg\u002Fm\\^2 or higher","20 Years",{"count":115,"type":22},60,[54],"This randomized, placebo-controlled pilot study aims to evaluate the effects of probiotic supplementation on sperm quality in male patients diagnosed with infertility. Male infertility accounts for approximately 40% of all infertility cases and is closely related to abnormalities in sperm count, motility, and morphology. Factors such as oxidative stress, inflammation, and DNA fragmentation are known to impact sperm function and subsequent fertilization potential negatively.\n\nProbiotics are microorganisms that confer health benefits by improving the intestinal microenvironment and regulating immunity. Emerging research suggests that probiotics may reduce oxidative stress and DNA fragmentation in men with asthenozoospermia; however, clinical data on human sperm remains limited. This study seeks to determine whether specific probiotic strains can improve sperm parameters and function in patients with unexplained oligozoospermia, asthenozoospermia, or oligoasthenoteratozoospermia.\n\nThe study will enroll 60 male participants aged 20 to 45 who meet specific inclusion criteria, including a sperm concentration of less than 50 million\u002FmL, motility less than 40%, and normal morphology (Kruger) less than 4%. Participants will be randomly assigned to either an experimental group receiving probiotics or a control group receiving a placebo for approximately 100 days.\n\nSemen samples will be collected and analyzed at three time points: before the intervention (Day 0), during the intervention (Day 60), and at the end of the study (Day 100). The primary objective is to assess changes in sperm concentration, motility, and morphology using the Computer-Aided Sperm Analysis (CASA) system. Secondary objectives include evaluating sperm DNA integrity using the Sperm Chromatin Structure Assay (SCSA) by flow cytometry and assessing sperm function via the acrosome reaction assay. The results of this pilot study will help determine the potential therapeutic role of probiotics in the management of male infertility.",[57,28,60,61,119],"Oligoasthenoteratozoospermia",[121,122,123,124,28,60],"Probiotics","Sperm Motility","Sperm DNA","Sperm Function","2026-01-08",{"date":127,"type":33},"2026-01-15",{"date":129,"type":33},"2023-09-16",{"date":131,"type":22},"2026-12-31",{"name":133,"class":80},"Mackay Memorial Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":140,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100487584","the-association-of-gut-microbiota-and-spermatogenic-dysfunction-100487584","NCT05628987","The Association of Gut Microbiota and Spermatogenic Dysfunction","Inclusion Criteria:\n\n* Aged 18 to 45 years, males\n* Body Mass Index (BMI):18.5-29.9 kg\u002Fm\\^2\n* After an abstinence period of 2-7 days, two abnormal semen analysis, the absence of spermatozoa from both replicates will be included in the azoospermia group, the total sperm number (\\\u003C39\\*10\\^6 per ejaculate) or the sperm concentration ( \\\u003C 15 \\* 10\\^6 per ml) will be oligozoospermia group, the progressive motility (PR) (\\\u003C 32%) will be asthenozoospermia group; the percentage of morphologically normal spermatozoa (\\\u003C4%) will be teratozoospermia group\n* Willing to provide feces, urine, blood samples, able to complete study questionnaires aimed at lifestyle factors (cigarette smoking, high temperature environment and others ) and other data collection instruments (e.g. physical activity, food frequency questionnaire, stress and others)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 45 years\n* History of Zocanidin, Vitamin E, antibiotics, clyster, gastrointestinal endoscope in the past 30 days, or other drugs known to interact with semen quality or gut microbiota, history of high alcohol consumption (liquor over 200 ml, beer over 1000 ml) in the past 7 days or drinking every week in the past month\n* A known genetic cause of male factor spermatogenesis dysfunction, including chromosomal or gene disorders (e.g. Y chromosome deletions, CFTR mutation)\n* History of male reproductive system (e.g. testis, epididymis, seminiferous duct and others) damage, surgery, tumor or infection\n* History of Crohn's disease, ulcerative colitis, acute gastrointestinal disease, renal failure, liver cirrhosis, hypoplasia, X-rays exposure and other diseases related to spermatogenic dysfunction, history of intestinal gastrointestinal surgery (exclude appendix surgery)\n* History of psychoses or other mental conditions that would result in cognitive impairment and inability to participate in any part of this study including the informed consent process",{"count":141,"type":22},306,"This is a multicenter, case-control study that aims to investigate the relationship between microbiota and sperm quality via stool, blood, and urine microbiome, metabolomics, and collected clinical metadata. The results of the spermatogenic dysfunction, including aspermia, oligozoospermia, asthenozoospermia, and teratozoospermia, will be compared to normal basic semen analysis utilizing the World Health Organization (WHO) semen analysis procedure 5th edition.",[144,145,28,60,61],"Infertility, Male","Azoospermia",[147,144,148],"Microbiota","Sperm","2024-07-22",{"date":151,"type":33},"2024-07-24",{"date":153,"type":33},"2023-02-20",{"date":155,"type":22},"2025-06-30",{"name":157,"class":80},"Zhujiang Hospital",3]